The 5 most recent market catalysts affecting $SUPN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 95
Supernus Pharma shares are trading higher after the company reported better-than-expected Q2 financial results. The company also announced a merger with Indivior Pharma to create diversified, CNS biopharmaceutical company.
This headline represents a major corporate catalyst for both Supernus Pharma and Indivior Pharma. The combination of better-than-expected earnings for Supernus and a strategic merg…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 95
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in a tax-free all-stock deal, creating a significant player in the CNS biopharmaceutical space. This merger is hig…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 92
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate
Supernus Pharmaceuticals (SUPN) announced Q2 adjusted EPS of $0.53, handily beating the consensus estimate of $0.42 by over 26%. This is a significant positive surprise, demonstrat…
Aug 3, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Monday's Pre-Market Session
The filing details pre-market trading activity for 12 healthcare stocks, highlighting both significant gainers and losers. The most notable event is Supernus Pharmaceuticals' (SUPN…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 95
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock transaction, forming a new CNS biopharmaceutical company. This deal is significant as it creates a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.